CORCEPT THERAPEUTICS INC

Corcept Insider Selling: James N. Wilson’s 10‑b‑5‑1 plan sale shows disciplined liquidity moves, not a confidence hit—investors can still see long‑term growth potential.

Corcept’s insider trades reveal a shift in oncology strategy – see how a senior executive’s sale and early GR‑II trials may signal new R&D priorities.

Insider sales at Corcept Therapeutics reveal balanced liquidity needs and strong biotech fundamentals—investors should monitor 10‑b‑5 activity for market clues.